secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001193125-23-199395
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA aligns with DBV on COMFORT safety study designs for toddlers (1-3) and children (4-7); cash $174M, H1 loss $44.8M
--------------------------------------------------------------------------------

- FDA agreed on COMFORT Toddlers design: 6-month, 3:1 randomization, ~400 subjects, ages 1-3, no oral food challenge required.
- FDA feedback on COMFORT Children (ages 4-7) consistent with Dec 2022 agreement; studies target ~600 on active treatment per group.
- Cash and equivalents $174M as of June 30, 2023 (down from $209.2M at Dec 31, 2022); H1 net loss $44.8M ($0.48/share).
- Operating expenses $50.7M in H1 (+$6.1M YoY); R&D up to $33.6M driven by VITESSE trial initiation in March 2023.
- Company raised $7.8M via ATM in June 2023; EPITOPE data published in NEJM in May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523199395/0001193125-23-199395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523199395/d533459d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-199395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer